medigraphic.com
ISSN 2500-7106 (Digital)
ISSN 0123-2576 (Impreso)
Medicina & Laboratorio

2022, Número 1

<< Anterior Siguiente >>

Medicina & Laboratorio 2022; 26 (1)


Reacciones de hipersensibilidad a quimioterapéuticos y biológicos

Martínez-Castillo DM, Ardila-Herrera JC, Calle-Álvarez AM, Chinchilla-Mejía CF

Idioma: Español
Referencias bibliográficas: 76
Paginas: 63-80
Archivo PDF: 125.80 Kb.


RESUMEN

Las reacciones a medicamentos han aumentado con el tiempo, estas implican ahora una carga importante de enfermedad, principalmente en los servicios de hospitalización. Los agentes quimioterapéuticos y biológicos son fármacos utilizados con frecuencia en enfermedades reumatológicas y neoplasias de diferente orden. Las reacciones de hipersensibilidad a quimioterapéuticos y monoclonales impactan en la calidad de vida, el pronóstico y la mortalidad de los pacientes con enfermedades autoinmunes y cáncer, es por eso que deben ser reconocidas y manejadas por un equipo de trabajo multidisciplinar. La desensibilización es una herramienta terapéutica que ofrece grandes beneficios a los pacientes con reacciones de hipersensibilidad, permitiéndoles la utilización de medicamentos de primera línea de manera segura y costoefectiva, con un impacto importante en la morbilidad y mortalidad de estos pacientes. El objetivo de este artículo fue revisar la información y evidencia más reciente sobre las reacciones de hipersensibilidad a quimioterapéuticos y biológicos, y los datos sobre las opciones de desensibilización con estos medicamentos y su desenlace.


REFERENCIAS (EN ESTE ARTÍCULO)

  1. Jiménez ÓE, Navarro-Pemán C, González-Rubio F, Lanuza-Giménez FJ, Montesa-Lou C.Análisis de la incidencia y de las característicasclínicas de las reacciones adversas a medicamentosde uso humano en el medio hospitalario.Rev Esp Salud Publica 2017;91:1-17.

  2. Organización Mundial de la Salud. Vigilanciade la seguridad de los medicamentos. Sistemade notificación para el público en general.Ginebra, Suiza: OMS; 2012. Acceso 15 de juliode 2021. Disponible en https://www.who.int/medicines/areas/quality_safety/safety_efficacy/WHO-UMC_ReportingGeneralPublic-ESPGRA3Final.pdf.

  3. Bush T. Adverse drug reactions in hospitalizedpatients. JAMA 1998;280:1742-1744.

  4. Gomes ER, Demoly P. Epidemiology of hypersensitivitydrug reactions. Curr Opin AllergyClin Immunol 2005;5:309-316. https://doi.org/10.1097/01.all.0000173785.81024.33.

  5. Thong BY, Tan TC. Epidemiology and riskfactors for drug allergy. Br J Clin Pharmacol2011;71:684-700. https://doi.org/10.1111/j.1365-2125.2010.03774.x.

  6. Jares EJ, Sánchez-Borges M, Cardona-VillaR, Ensina LF, Arias-Cruz A, Gómez M, et al.Multinational experience with hypersensitivitydrug reactions in Latin America. Ann AllergyAsthma Immunol 2014;113:282-289. https://doi.org/10.1016/j.anai.2014.06.019.

  7. Thong BY, Leong KP, Tang CY, Chng HH.Drug allergy in a general hospital: Resultsof a novel prospective inpatient reportingsystem. Ann Allergy Asthma Immunol2003;90:342-347. https://doi.org/10.1016/s1081-1206(10)61804-2.

  8. Giavina-Bianchi P, Jares E, Aun MV, ThongB. Drug hypersensitivity reactions in the Americas:Similarities and differences. Ann AllergyAsthma Immunol 2019;122:447-448. https://doi.org/10.1016/j.anai.2019.02.007.

  9. Gülsen A, Wedi B, Jappe U. Hypersensitivityreactions to biologics (part I): allergy as animportant differential diagnosis in compleximmune-derived adverse events. AllergoJ 2020;29:32-61. https://doi.org/10.1007/s15007-020-2550-1.

  10. Hong D, Sloane DE. Hypersensitivity to monoclonalantibodies used for cancer and inflammatoryor connective tissue diseases. Ann AllergyAsthma Immunol 2019;123:35-41. https://doi.org/10.1016/j.anai.2019.04.015.

  11. Patel SV, Khan DA. Adverse reactions to biologictherapy. Immunol Allergy Clin North Am2017;37:397-412. https://doi.org/10.1016/j.iac.2017.01.012.

  12. Sala-Cunill A, Luengo O, Cardona V. Biologicsand anaphylaxis. Curr Opin Allergy Clin Immunol2019;19:439-446. https://doi.org/10.1097/aci.0000000000000550.

  13. Quercia O, Emiliani F, Foschi FG, Stefanini GF.Adalimumab desensitization after anaphylacticreaction. Ann Allergy Asthma Immunol2011;106:547-548. https://doi.org/10.1016/j.anai.2011.03.014.

  14. Soyer O, Demir S, Bilginer Y, Batu ED, SonmezHE, Arıcı ZS, et al. Severe hypersensitivityreactions to biological drugs in children withrheumatic diseases. Pediatr Allergy Immunol2019;30:833-840. https://doi.org/10.1111/pai.13114.

  15. Akarsu A, Soyer O, Sekerel BE. Hypersensitivityreactions to biologicals: From bench to bedside.Curr Treat Options Allergy 2020;7:71-83.https://doi.org/10.1007/s40521-020-00242-2.

  16. Sanchez-Piedra C, Hernández-Miguel MV,Manero J, Roselló R, Sánchez-Costa JT, Rodríguez-Lozano C, et al. Objetivos y metodologíade la fase III de BIOBADASER. Reumatol Clin2019;15:229-236. https://doi.org/10.1016/j.reuma.2017.08.001.

  17. Vultaggio A, Castells MC. Hypersensitivityreactions to biologic agents. Immunol AllergyClin North Am 2014;34:615-632. https://doi.org/10.1016/j.iac.2014.04.008.

  18. Vultaggio A, Matucci A, Parronchi P, Rossi O,Palandri F, Romagnani S, et al. Safety and tolerabilityof infliximab therapy: Suggestions andcriticisms based on wide clinical experience. IntJ Immunopathol Pharmacol 2008;21:367-374.https://doi.org/10.1177/039463200802100214.

  19. Pichler WJ. Adverse side-effects to biologicalagents. Allergy 2006;61:912-920. https://doi.org/10.1111/j.1398-9995.2006.01058.x.

  20. Chitnavis M, Stein DJ, Commins S, SchuylerAJ, Behm B. First-dose anaphylaxis to infliximab:a case of mammalian meat allergy. JAllergy Clin Immunol Pract 2017;5:1425-1426.https://doi.org/10.1016/j.jaip.2017.04.044.

  21. Arnold DF, Misbah SA. Cetuximab-inducedanaphylaxis and IgE specific for galactose-alpha-1,3-galactose. N Engl J Med2008;358:2735-2736. https://doi.org/10.1056/NEJMc080834.

  22. Price KS, Hamilton RG. Anaphylactoid reactionsin two patients after omalizumab administrationafter successful long-term therapy.Allergy Asthma Proc 2007;28:313-319. https://doi.org/10.2500/aap.2007.28.3003.

  23. Perino E, Freymond N, Devouassoux G, NicolasJF, Berard F. Xolair-induced recurrent anaphylaxisthrough sensitization to the excipientpolysorbate. Ann Allergy Asthma Immunol2018;120:664-666. https://doi.org/10.1016/j.anai.2018.02.018.

  24. Corominas M, Gastaminza G, Lobera T. Hypersensitivityreactions to biological drugs. J InvestigAllergol Clin Immunol 2014;24:212-225.

  25. del Carmen-Sancho M, Breslow R, SloaneD, Castells M. Desensitization for hypersensitivityreactions to medications. Chem ImmunolAllergy 2012;97:217-233. https://doi.org/10.1159/000335637.

  26. Khan DA. Hypersensitivity and immunologicreactions to biologics: opportunities forthe allergist. Ann Allergy Asthma Immunol2016;117:115-120. https://doi.org/10.1016/j.anai.2016.05.013.

  27. Wing M. Monoclonal antibody first dose cytokinerelease syndromes-mechanisms and prediction.J Immunotoxicol 2008;5:11-15. https://doi.org/10.1080/15476910801897433.

  28. Yildizhan E, Kaynar L. Cytokine release syndrome.J Oncol Sci 2018;4:134-141. https://doi.org/10.1016/j.jons.2018.09.002.

  29. Reber LL, Hernandez JD, Galli SJ. Thepathophysiology of anaphylaxis. J AllergyClin Immunol 2017;140:335-348. https://doi.org/10.1016/j.jaci.2017.06.003.

  30. Isabwe GAC, Garcia-Neuer M, de Las Vecillas-Sanchez L, Lynch DM, Marquis K, Castells M.Hypersensitivity reactions to therapeutic monoclonalantibodies: Phenotypes and endotypes.J Allergy Clin Immunol 2018;142:159-170.https://doi.org/10.1016/j.jaci.2018.02.018.

  31. Bavbek S, Ataman Ş, Akıncı A, Castells M.Rapid subcutaneous desensitization for themanagement of local and systemic hypersensitivityreactions to etanercept and adalimumabin 12 patients. J Allergy Clin Immunol Pract2015;3:629-632. https://doi.org/10.1016/j.jaip.2015.01.009.

  32. O'Meara S, Nanda KS, Moss AC. Antibodiesto infliximab and risk of infusion reactions in patientswith inflammatory bowel disease: a systematicreview and meta-analysis. Inflamm BowelDis 2014;20:1-6. https://doi.org/10.1097/01.MIB.0000436951.80898.6d.

  33. Lowndes S, Darby A, Mead G, Lister A. Stevens-Johnson syndrome after treatment withrituximab. Ann Oncol 2002;13:1948-1950.https://doi.org/10.1093/annonc/mdf350.

  34. Urosevic-Maiwald M, Harr T, French LE,Dummer R. Stevens-Johnson syndrome andtoxic epidermal necrolysis overlap in a patientreceiving cetuximab and radiotherapyfor head and neck cancer. Int J Dermatol2012;51:864-867. https://doi.org/10.1111/j.1365-4632.2011.05356.x.

  35. Karmacharya P, Poudel DR, Pathak R, DonatoAA, Ghimire S, Giri S, et al. Rituximab-inducedserum sickness: A systematic review. SeminArthritis Rheum 2015;45:334-340. https://doi.org/10.1016/j.semarthrit.2015.06.014.

  36. Maggi E, Vultaggio A, Matucci A. Acute infusionreactions induced by monoclonal antibodytherapy. Expert Rev Clin Immunol 2011;7:55-63. https://doi.org/10.1586/eci.10.90.

  37. Vitte J, Amadei L, Gouitaa M, Mezouar S, ZieleskiewiczL, Albanese J, et al. Paired acutebaselineserum tryptase levels in perioperativeanaphylaxis: An observational study. Allergy2019;74:1157-1165. https://doi.org/10.1111/all.13752.

  38. Brown SG. Clinical features and severity gradingof anaphylaxis. J Allergy Clin Immunol2004;114:371-376. https://doi.org/10.1016/j.jaci.2004.04.029.

  39. Brockow K, Garvey LH, Aberer W, Atanaskovic-Markovic M, Barbaud A, Bilo MB, et al. Skintest concentrations for systemically administereddrugs -- an ENDA/EAACI Drug Allergy InterestGroup position paper. Allergy 2013;68:702-712. https://doi.org/10.1111/all.12142.

  40. Hong DI, Dioun AF. Indications, protocols, andoutcomes of drug desensitizations for chemotherapyand monoclonal antibodies in adults andchildren. J Allergy Clin Immunol Pract 2014;2:13-19. https://doi.org/10.1016/j.jaip.2013.11.007.

  41. Bonamichi-Santos R, Castells M. Diagnosesand management of drug hypersensitivity andanaphylaxis in cancer and chronic inflammatorydiseases: Reactions to taxanes and monoclonalantibodies. Clin Rev Allergy Immunol2018;54:375-385. https://doi.org/10.1007/s12016-016-8556-5.

  42. Castells MC. Anaphylaxis to chemotherapyand monoclonal antibodies. Immunol AllergyClin North Am 2015;35:335-348. https://doi.org/10.1016/j.iac.2015.01.011.

  43. Chabner BA, Roberts TG. Chemotherapy andthe war on cancer. Nat Rev Cancer 2005;5:65-72. https://doi.org/10.1038/nrc1529.

  44. Picard M, Castells MC. Re-visiting hypersensitivityreactions to taxanes: A comprehensivereview. Clin Rev Allergy Immunol2015;49:177-191. https://doi.org/10.1007/s12016-014-8416-0.

  45. Turgay-Yagmur I, Guzelkucuk Z, Yarali N, OzyorukD, Toyran M, Civelek E, et al. Evaluationof hypersensitivity reactions to cancer chemotherapeuticagents in pediatric patients. Ann AllergyAsthma Immunol 2020;124:350-356. https://doi.org/10.1016/j.anai.2020.01.010.

  46. Henry A, Charpiat B, Perol M, Vial T, de SaintHilaire PJ, Descotes J. Paclitaxel hypersensitivityreactions: assessment of the utility of a test-doseprogram. Cancer J 2006;12:237-245. https://doi.org/10.1097/00130404-200605000-00013.

  47. Ratanajarusiri T, Sriuranpong V, SitthideatphaiboonP, Poovoravan N, Vinayanuwat C, ParinyanitikulN, et al. A Difference in the incidencesof hypersensitivity reactions to original and generictaxanes. Chemotherapy 2017;62:134-139.https://doi.org/10.1159/000450748.

  48. Koshiba H, Hosokawa K, Kubo A, Miyagi Y,Oda T, Miyagi Y, et al. Incidence of carboplatin-related hypersensitivity reactions in Japanesepatients with gynecologic malignancies. Int JGynecol Cancer 2009;19:460-465. https://doi.org/10.1111/IGC.0b013e3181a1bf2e.

  49. Parel M, Ranchon F, Nosbaum A, You B, VantardN, Schwiertz V, et al. Hypersensitivity tooxaliplatin: clinical features and risk factors.BMC Pharmacol Toxicol 2014;15:1. https://doi.org/10.1186/2050-6511-15-1.

  50. Polyzos A, Tsavaris N, Gogas H, Souglakos J,Vambakas L, Vardakas N, et al. Clinical featuresof hypersensitivity reactions to oxaliplatin: a10-year experience. Oncology 2009;76:36-41.https://doi.org/10.1159/000178163.

  51. Sohn KH, Kang DY, Kim JY, Lee SY, Lee KH,Han SW, et al. Incidence and risk of oxaliplatin-induced hypersensitivity in patients withasymptomatic prior exposure: A prospectiveobservational study. J Allergy Clin ImmunolPract 2018;6:1642-1648.e1642. https://doi.org/10.1016/j.jaip.2017.12.026.

  52. Tham EH, Cheng YK, Tay MH, AlcasabasAP, Shek LP. Evaluation and managementof hypersensitivity reactions to chemotherapyagents. Postgrad Med J 2015;91:145-150. https://doi.org/10.1136/postgradmedj-2014-132686.

  53. Demoly P, Adkinson NF, Brockow K, CastellsM, Chiriac AM, Greenberger PA, et al. InternationalConsensus on drug allergy. Allergy2014;69:420-437. https://doi.org/10.1111/all.12350.

  54. Caiado J, Venemalm L, Pereira-Santos MC,Costa L, Barbosa MP, Castells M. Carboplatin-,oxaliplatin-, and cisplatin-specific IgE:cross-reactivity and value in the diagnosis ofcarboplatin and oxaliplatin allergy. J AllergyClin Immunol Pract 2013;1:494-500. https://doi.org/10.1016/j.jaip.2013.06.002.

  55. Kolomeyevskaya NV, Lele SB, Miller A, RiebandtGC, Blum BL, Odunsi KO, et al. Oxaliplatinis a safe alternative option for patientswith recurrent gynecologic cancers after hypersensitivityreaction to Carboplatin. Int JGynecol Cancer 2015;25:42-48. https://doi.org/10.1097/igc.0000000000000307.

  56. Zweizig S, Roman LD, Muderspach LI. Deathfrom anaphylaxis to cisplatin: a case report.Gynecol Oncol 1994;53:121-122. https://doi.org/10.1006/gyno.1994.1098.

  57. Rose PG, Metz C, Link N. Desensitizationwith oxaliplatin in patients intolerant of carboplatindesensitization. Int J Gynecol Cancer2014;24:1603-1606. https://doi.org/10.1097/igc.0000000000000295.

  58. Dizon DS, Schwartz J, Rojan A, Miller J, PiresL, Disilvestro P, et al. Cross-sensitivity betweenpaclitaxel and docetaxel in a women's cancersprogram. Gynecol Oncol 2006;100:149-151.https://doi.org/10.1016/j.ygyno.2005.08.004.

  59. Sánchez-Muñoz A, Jiménez B, García-TapiadorA, Romero-García G, Medina L, NavarroV, et al. Cross-sensitivity between taxanes inpatients with breast cancer. Clin Transl Oncol2011;13:904-906. https://doi.org/10.1007/s12094-011-0753-3.

  60. Picard M, Pur L, Caiado J, Giavina-Bianchi P,Galvão VR, Berlin ST, et al. Risk stratificationand skin testing to guide re-exposure in taxane-induced hypersensitivity reactions. J AllergyClin Immunol 2016;137:1154-1164.e1112.https://doi.org/10.1016/j.jaci.2015.10.039.

  61. Pellegrino B, Boggiani D, Tommasi C, PalliD, Musolino A. Nab-paclitaxel after docetaxelhypersensitivity reaction: case report and literaturereview. Acta Biomed 2017;88:329-333.https://doi.org/10.23750/abm.v88i3.6138.

  62. Picard M. Management of hypersensitivityreactions to taxanes. Immunol Allergy ClinNorth Am 2017;37:679-693. https://doi.org/10.1016/j.iac.2017.07.004.

  63. Otani IM, Wong J, Banerji A. Platinum chemotherapyhypersensitivity: Prevalence andmanagement. Immunol Allergy Clin North Am2017;37:663-677. https://doi.org/10.1016/j.iac.2017.06.003.

  64. Markman M, Zanotti K, Peterson G, Kulp B,Webster K, Belinson J. Expanded experiencewith an intradermal skin test to predict forthe presence or absence of carboplatin hypersensitivity.J Clin Oncol 2003;21:4611-4614.https://doi.org/10.1200/jco.2003.05.539.

  65. Pagani M, Bavbek S, Dursun AB, BonadonnaP, Caralli M, Cernadas J, et al. Role of skin testsin the diagnosis of immediate hypersensitivityreactions to taxanes: Results of a multicenterstudy. J Allergy Clin Immunol Pract 2019;7:990-997. https://doi.org/10.1016/j.jaip.2018.09.018.

  66. Giavina-Bianchi P, Galvão VR, Picard M, CaiadoJ, Castells MC. Basophil activation test isa relevant biomarker of the outcome of rapiddesensitization in platinum compounds-allergy.J Allergy Clin Immunol Pract 2017;5:728-736.https://doi.org/10.1016/j.jaip.2016.11.006.

  67. Cernadas JR, Brockow K, Romano A, AbererW, Torres MJ, Bircher A, et al. General considerationson rapid desensitization for drug hypersensitivity- a consensus statement. Allergy2010;65:1357-1366. https://doi.org/10.1111/j.1398-9995.2010.02441.x.

  68. Kendirlinan R, Gümüşburun R, Çerçi P, ÖzbekE, Altıner S, Çelebi Sözener Z, et al.Rapid drug desensitization with chemotherapeutics(platins, taxanes, and others): A single-center retrospective study. Int Arch AllergyImmunol 2019;179:114-122. https://doi.org/10.1159/000496745.

  69. Caimmi S, Caffarelli C, Saretta F, Liotti L, CrisafulliG, Cardinale F, et al. Drug desensitizationin allergic children. Acta Biomed 2019;90:20-29.https://doi.org/10.23750/abm.v90i3-S.8158.

  70. Castells MC, Tennant NM, Sloane DE, Hsu FI,Barrett NA, Hong DI, et al. Hypersensitivity reactionsto chemotherapy: outcomes and safetyof rapid desensitization in 413 cases. J AllergyClin Immunol 2008;122:574-580. https://doi.org/10.1016/j.jaci.2008.02.044.

  71. Sloane D, Govindarajulu U, Harrow-MortellitiJ, Barry W, Hsu FI, Hong D, et al. Safety, costs,and efficacy of rapid drug desensitizations tochemotherapy and monoclonal antibodies. JAllergy Clin Immunol Pract 2016;4:497-504.https://doi.org/10.1016/j.jaip.2015.12.019.

  72. Karaatmaca B, Aytac S, Sahiner UM, SekerelBE, Soyer O. Successful oral desensitizationwith dasatinib in delayed cutaneous hypersensitivityreactions. Ann Allergy Asthma Immunol2019;123:216-217. https://doi.org/10.1016/j.anai.2019.05.011.

  73. Bavbek S, Lee MJ. Subcutaneous injectabledrugs hypersensitivity and desensitization:Insulin and monoclonal antibodies. ImmunolAllergy Clin North Am 2017;37:761-771.https://doi.org/10.1016/j.iac.2017.06.001.

  74. Demir S, Soyer O, Bilginer Y, Sag E, SahinerUM, Buyuktiryaki B, et al. Desensitisationovercomes rituximab- and tocilizumab-relatedimmediate hypersensitivity in childhood. ClinExp Rheumatol 2020;38:552-557.

  75. Lopez-Gonzalez P, Madrigal-Burgaleta R,Carpio-Escalona LV, Bernal-Rubio L, GuerraE, Berges-Gimeno MP, et al. Assessment ofantihistamines and corticosteroids as premedicationin rapid drug desensitization to paclitaxel:Outcomes in 155 procedures. J AllergyClin Immunol Pract 2018;6:1356-1362. https://doi.org/10.1016/j.jaip.2017.11.013.

  76. Fouda GE, Bavbek S. Rituximab hypersensitivity:From clinical presentation to management.Front Pharmacol 2020;11:572863. https://doi.org/10.3389/fphar.2020.572863.




2020     |     www.medigraphic.com